Related references
Note: Only part of the references are listed.Intracerebroventricular delivery of glucocerebrosidase reduces substrates and increases lifespan in a mouse model of neuronopathic Gaucher disease
M. A. Cabrera-Salazar et al.
EXPERIMENTAL NEUROLOGY (2010)
Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated α-synuclein gene mutations precede central nervous system changes
Yien-Ming Kuo et al.
HUMAN MOLECULAR GENETICS (2010)
Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits
Ying Sun et al.
HUMAN MOLECULAR GENETICS (2010)
Interaction between parkin and mutant glucocerebrosidase variants: a possible link between Parkinson disease and Gaucher disease
Idit Ron et al.
HUMAN MOLECULAR GENETICS (2010)
Association of Glucocerebrosidase Mutations With Dementia With Lewy Bodies
Lorraine N. Clark et al.
ARCHIVES OF NEUROLOGY (2009)
Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human α-synuclein in transgenic mouse brain
Kenneth D. Cronin et al.
HUMAN MOLECULAR GENETICS (2009)
Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: A biological link between Gaucher disease and parkinsonism
Amy B. Manning-Bog et al.
NEUROTOXICOLOGY (2009)
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
E. Sidransky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo
Valerie Cullen et al.
MOLECULAR BRAIN (2009)
Glucocerebrosidase gene mutations - A risk factor for Lewy body disorders
Ignacio F. Mata et al.
ARCHIVES OF NEUROLOGY (2008)
Cathepsin D is the main lysosomal enzyme involved in the degradation of α-synuclein and generation of its carboxy-terminally truncated species
Daniel Sevlever et al.
BIOCHEMISTRY (2008)
Optimization and Validation of Two Miniaturized Glucocerebrosidase Enzyme Assays for High Throughput Screening
Daniel J. Urban et al.
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING (2008)
Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration
Brit Mollenhauer et al.
EXPERIMENTAL NEUROLOGY (2008)
Emerging pathways in genetic Parkinson's disease: Potential role of ceramide metabolism in Lewy body disease
Jose Bras et al.
FEBS JOURNAL (2008)
GATA transcription factors directly regulate the Parkinson's disease-linked gene α-synuclein
Clemens R. Scherzer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity
Liyan Qiao et al.
Molecular Brain (2008)
Parkinson disease, 10 years after its genetic revolution - Multiple clues to a complex disorder
Christine Klein et al.
NEUROLOGY (2007)
Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease
L. N. Clark et al.
NEUROLOGY (2007)
Three classes of gluclocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease
Wei Zheng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Deciphering the role of heterozygous mutations in genes associated with parkinsonism
Christine Klein et al.
LANCET NEUROLOGY (2007)
Small molecules enhance autophagy and reduce toxicity in Huntington's disease models
Sovan Sarkar et al.
NATURE CHEMICAL BIOLOGY (2007)
Structure of acid β-glucosidase with pharmacological chaperone provides insight into Gaucher disease
Raquel L. Lieberman et al.
NATURE CHEMICAL BIOLOGY (2007)
Phosphorylation of Ser-129 is the dominant pathological modification of α-synuclein in familial and sporadic Lewy body disease
John P. Anderson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Glucocerebrosidase mutations are an important risk factor for Lewy body disorders
O. Goker-Alpan et al.
NEUROLOGY (2006)
Identification of rotenone-induced modifications in α-synuclein using affinity pull-down and tandem mass spectrometry
H Mirzaei et al.
ANALYTICAL CHEMISTRY (2006)
Dopamine covalently modifies and functionally inactivates parkin
MJ LaVoie et al.
NATURE MEDICINE (2005)
Gaucher disease mouse models:: point mutations at the acid β-glucosidase locus combined with low-level prosaposin expression lead to disease variants
Y Sun et al.
JOURNAL OF LIPID RESEARCH (2005)
Analysis of the glucocerebrosidase gene in Parkinson's disease
C Sato et al.
MOVEMENT DISORDERS (2005)
Glucocerebrosidase mutations in subjects with parkinsonism
A Lwin et al.
MOLECULAR GENETICS AND METABOLISM (2004)
Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews
J Aharon-Peretz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
α-synuclein is degraded by both autophagy and the proteasome
JL Webb et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Viable mouse models of acid beta-glucosidase deficiency - The defect in Gaucher disease
YH Xu et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies
MG Schlossmacher et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
α-synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins
R Sharon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Human glucocerebrosidase: heterologous expression of active site mutants in murine null cells
SL Fabrega et al.
GLYCOBIOLOGY (2000)
Share Paper
